Abstract

Alzheimer’s disease (AD) is biologically defined by the accumulation of β-amyloid (Aβ) plaques and phosphorylated tau (P-tau) tangles, which appear decades before cognitive symptoms (Jack et al., 2018). Early detection and targeted intervention remain limited by the lack of scalable, non-invasive diagnostics and by the difficulty of delivering therapeutics across the blood–brain barrier (BBB) (Gao et al., 2025; Kwak et al., 2024; Meairs, 2015). This paper proposes the Quantum-CRISPR Epigenome-Targeted Theranostic System (Q-CETS), a platform integrating quantum nanodiamond biomarker sensing with MRI-guided, Focused Ultrasound (FUS) delivery of dCas9-based epigenome-modifying tools. Q-CETS aims to identify individuals in the earliest stages of the Alzheimer’s continuum and intervene directly in the molecular drivers of pathology. By combining non-invasive early detection and precise gene-regulatory modulation, Q-CETS establishes a comprehensive, biologically targeted framework for preventing AD before neurodegeneration begins.

Page 2 visual content
Page 2 visual content

I. What Would It Measure?

The Q-CETS diagnostic module would measure the earliest molecular signals of Alzheimer’s disease: soluble Aβ oligomers and P-tau species circulating in peripheral biofluids. These biomarkers are the foundation of the AT(N) classification framework and precede clinical symptoms by up to twenty years, making them ideal targets for population-level, presymptomatic screening (Jack et al., 2018). Q-CETS employs Quantum Sensing Nanodiamonds (QSNPs) containing nitrogen-vacancy (NV) centers, which detect nanoscale magnetic and electric field perturbations generated when functionalized antibodies bind Aβ or P-tau. Binding events modulate NV fluorescence lifetimes, creating a quantifiable optical signal that corresponds to biomarker concentration (Tan et al., 2022; Chaparro et al., 2023; Barry et al., 2020). This enables a novel, quantum-level molecular measurement in peripheral fluids such as blood or saliva—an approach fundamentally different from PET imaging or CSF sampling. Because NV-center fluorescence responds on microsecond timescales and is highly sensitive to small biomolecular interactions, the system could deliver instantaneous biomarker readouts during routine clinical workflows (National Institute on Aging, 2024). Q-CETS therefore fills a critical gap by providing sensitive, non-invasive, scalable early detection grounded in the physical behavior of quantum spin states.

Page 3 visual content
Page 3 visual content
Page 4 visual content
Page 4 visual content

II. What Would the Equipment Look Like?

Q-CETS consists of two linked technologies: a diagnostic device for early identification and a therapeutic delivery system for targeted intervention. The diagnostic device, the Quantum Early Test (QET-Scanner), is a compact benchtop instrument operating through low-power laser excitation and high-precision photodetection of NV fluorescence. It contains microfluidic channels for sample handling and a processing unit running machine-learning models that classify Aβ and P-tau levels. With a size comparable to a standard blood analyzer and weighing under 20 pounds, the QET-Scanner could be deployed in primary-care clinics, community centers, or pharmacies for rapid screening (Tan et al., 2022; Zhang et al., 2024). The therapeutic system is used only when Q-CETS indicates elevated risk. It consists of a biodegradable polymeric nanocarrier made from poly(β-amino ester) (PBAE) coated with polyethylene glycol to improve circulation time and reduce immune activation (Kwak et al., 2024). The nanoparticle includes embedded SPIONs, which allow MRI visualization and magnetic steering (Chakraborty et al., 2023). It carries mRNA encoding a catalytically inactive Cas9 (dCas9) fused to epigenetic effector domains and paired with sgRNAs targeting AD-related genes such as APP, PSEN1, and MAPT. Delivery is guided by MRI and assisted by Focused Ultrasound, which temporarily opens the BBB through microbubble-assisted acoustic cavitation, permitting nanoparticles to reach deep brain targets safely (Meairs, 2015). The two devices rely on distinct physical principles—quantum coherence, optical fluorescence, magnetic resonance, and ultrasound propagation—yet together form a unified theranostic platform capable of both identifying and modulating the earliest stages of AD biology.

Page 5 visual content
Page 5 visual content
Page 6 visual content
Page 6 visual content

III. What Would the Data Look Like?

The diagnostic module generates optical emission data from NV-center fluorescence signals that shift based on molecular binding events. These measurements occur on microsecond timescales and require minimal computational processing aside from spectral deconvolution and machine-learning-based biomarker quantification (Tan et al., 2022). Output data include concentrations of Aβ and P-tau reported in pg/mL, along with automated AT-framework classification (Jack et al., 2018). Because measurements are performed on small fluid samples, data storage requirements are modest and allow near-instantaneous reporting. The therapeutic component generates MRI data representing the distribution and accumulation of SPION-labeled nanocarriers in targeted brain regions. T2*-weighted MRI sequences provide sub-millimeter spatial resolution, visualizing how nanoparticles travel through opened BBB regions and confirming their successful localization to hippocampal or cortical areas implicated in early AD (Chakraborty et al., 2023). Additional imaging overlays can display predicted dCas9 editing activity, integrating pre-intervention biomarker levels from the diagnostic module with post-intervention imaging. Data volumes range from megabytes to gigabytes depending on MRI duration, but standard clinical reconstruction methods and machine-learning-based prediction models streamline real-time interpretation (Meairs, 2015).

Page 7 visual content
Page 7 visual content
Page 8 visual content
Page 8 visual content

IV. What Are the Limitations and Challenges?

Despite its potential, Q-CETS faces significant biological, physical, and regulatory challenges. FUS must be carefully calibrated to ensure safe BBB opening without damaging vascular or neuronal tissue, and nanoparticle size must remain under approximately 100 nm to cross the BBB effectively, limiting payload capacity (Kwak et al., 2024; Meairs, 2015). NV-center quantum sensors are highly sensitive but susceptible to environmental noise and decoherence, requiring shielding and advanced signal-processing techniques to maintain accuracy (Barry et al., 2020; Zhang et al., 2024). Engineering challenges include producing nanocarriers with consistent size, charge, and magnetic properties at scale, ensuring long-term biocompatibility, and avoiding oxidative stress or immune responses associated with SPIONs or nanodiamond surfaces (Chakraborty et al., 2023). The integration of quantum diagnostics with gene-regulatory therapeutics also presents unprecedented regulatory complexity, as both fields are subject to strict translational and ethical standards. Biologically, dCas9-based epigenome editing must achieve stable yet reversible modulation of target gene expression while minimizing off-target effects. Delivering CRISPR machinery to long-lived neurons introduces uncertainties about duration of action and long-term safety (Kwak et al., 2024). Ethical concerns must also be addressed, particularly when intervening in asymptomatic individuals identified solely by molecular risk markers (Jack et al., 2018).

Page 9 visual content
Page 9 visual content
Page 10 visual content
Page 10 visual content

V. What Would This Enable?

If fully realized, Q-CETS would redefine both Alzheimer’s research and clinical practice. The QET-Scanner could deliver population-wide presymptomatic screening, identifying at-risk individuals in routine healthcare settings without radiation or invasive sampling (Jack et al., 2018). Personalized nanocarriers could then deliver epigenetic interventions tailored to each patient’s molecular and genetic risk profile, providing a precision-medicine approach capable of modulating Aβ and tau pathways before irreversible neurodegeneration occurs (Kwak et al., 2024). In research settings, Q-CETS would allow for longitudinal monitoring of disease-related biomarkers in combination with direct visualization of therapeutic effects, offering insights into early pathophysiology that remain beyond the reach of current imaging technologies. The platform could also be adapted to other neurodegenerative conditions characterized by protein aggregation or dysregulated gene expression, including Parkinson’s disease and frontotemporal dementia. By merging early detection with targeted molecular intervention, Q-CETS represents a shift from reactive treatment to proactive, biology-guided neuromedicine.

References

  1. Barry, J. F., Schloss, J. M., Bauch, E., Turner, M. J., Hart, C. A., Pham, L. M., & Walsworth, R. L. (2020). Sensitivity optimization for nv-diamond magnetometry. Reviews of Modern Physics, 92(1). https://doi.org/10.1103/revmodphys.92.015004
  2. Chakraborty, A., Mohapatra, S. S., Barik, S., Roy, I., Gupta, B., & Biswas, A. (2023). Impact of nanoparticles on amyloid beta-induced Alzheimer’s disease, tuberculosis, leprosy and cancer: A systematic review. Bioscience Reports, 43(2). https://doi.org/10.1042/bsr20220324
  3. Chaparro, C. I. P., Simões, B. T., Borges, J. P., Castanho, M. A. R. B., Soares, P. I. P., & Neves, V. (2023). A promising approach: Magnetic nanosystems for Alzheimer’s disease theranostics. Pharmaceutics, 15(9), 2316. https://doi.org/10.3390/pharmaceutics15092316
  4. OpenAI. (2025). DALL·E (Version X) [Text-to-image model]. https://chat.openai.com/
  5. Fadul, S. M., Arshad, A., & Mehmood, R. (2023). CRISPR-based epigenome editing: Mechanisms and applications. Epigenomics, 15(21), 1137–1155. https://doi.org/10.2217/epi-2023-0281
  6. Gao, L., Wang, J., & Bi, Y. (2025). Nanotechnology for neurodegenerative diseases: Recent progress in brain-targeted delivery, stimuli-responsive platforms, and organelle-specific therapeutics. International Journal of Nanomedicine, Volume 20(11015-11044), 11015–11044. https://doi.org/10.2147/ijn.s549893
  7. Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., & Sperling, R. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
  8. Kwak, G., Grewal, A., Hasan Slika, Mess, G., Li, H., Mohit Kwatra, Poulopoulos, A., Woodworth, G. F., Eberhart, C. G., Ko, H. S., Amir Manbachi, Caplan, J., Price, R. J., Tyler, B., & Suk, J. S. (2024). Brain nucleic acid delivery and genome editing via focused ultrasound-mediated blood–brain barrier opening and long-circulating nanoparticles. ACS Nano, 18(35), 24139–24153. https://doi.org/10.1021/acsnano.4c05270
  9. Meairs, S. (2015). Facilitation of drug transport across the blood–brain barrier with ultrasound and microbubbles. Pharmaceutics, 7(3), 275–293. https://doi.org/10.3390/pharmaceutics7030275
  10. National Institute on Aging. (2024, January 19). What happens to the brain in Alzheimer’s disease? National Institute on Aging. https://www.nia.nih.gov/health/alzheimers-causes-and-risk-factors/what-happens-brain-alzheimers-disease
  11. Selkoe, D. J., & Hardy, J. (2009). The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal. Journal of Neurochemistry, 110(4), 1129–1134. https://doi.org/10.1111/j.1471-4159.2009.06181.x
  12. Tan, Y., Hu, X., Hou, Y., & Chu, Z. (2022). Emerging diamond quantum sensing in bio-membranes. Membranes, 12(10), 957. https://doi.org/10.3390/membranes12100957
  13. Zhang, Y., He, Z., Tong, X., Garrett, D. C., Cao, R., & Wang, L. V. (2024). Quantum imaging of biological organisms through spatial and polarization entanglement. Science Advances, 10(10). https://doi.org/10.1126/sciadv.adk1495